An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

出版年份 2014 全文链接

标题

作者

关键词

出版物

Volume 20, Issue 23, Pages 5918-5926

出版商

American Association for Cancer Research (AACR)

发表日期

2014-09-27

DOI

10.1158/1078-0432.ccr-14-1143

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now